Key result
Prior hyperkalemia linked to ~130% greater recurrence risk in heart failure patients.
Why the study?
Hyperkalemia is linked to arrhythmias and sudden death, but evidence on its recurrence in heart failure patients is limited.
Cohort (n=15,512)
Yes
In a real-world cohort of heart failure patients not on outpatient potassium binders, hyperkalemia recurrence is highly common (49.5% at 12 months), with prior hyperkalemia, hypertension, and advanced CKD being the strongest predictors.
Recurrent hyperkalemia signals need for vigilant monitoring; leaves open optimal prevention strategies in CKD and immunosuppressed patients.
Background Hyperkalemia, a life-threatening electrolyte condition, is linked to arrhythmias and sudden death, but evidence on its recurrence in heart failure (HF) patients is limited. Methods We conducted a cohort study using de-identified EHR data from TriNetX Dataworks USA (study period: January 1, 2019, to June 30, 2023). HF patients who experienced hyperkalemia were included. Study outcomes included the percentage experiencing recurrent hyperkalemia (K+ >5.0 mmol/L), number and timing of recurrences, and K+ at each recurrence. Risk factors for hyperkalemia recurrence were identified using multivariable logistic regression and validated with Monte Carlo simulation. Subgroup analyses were performed for patients without baseline CKD (i.e., eGFR >60 mL/min/1.73 m² and no CKD/ESRD diagnosis). Results The study cohort comprised 15,512 patients (median age 68 years, 42.3% female, 60.5% White, 21.4% Black). Within 12 months, recurrent hyperkalemia was commonly observed in the full cohort (49.5%) and No-CKD subgroup (37.3%). Mean number of recurrences was 2.5 and 2.0, respectively; mean K+ at each recurrence was ∼5.5 mmol/L; and time to recurrence decreased with each successive event. Significant risk factors for recurrence included history of hyperkalemia (OR 2.3, 95% CI: 2.1–2.5), hypertension, advanced CKD, immunosuppressant therapy, and malignancy. Conclusions In this real-world cohort of HF patients, hyperkalemia recurrence was common regardless of renal function status, with increasing frequency and decreasing time intervals between subsequent recurrences. History of hyperkalemia was the strongest risk factor for recurrent hyperkalemia. Further research focused on hyperkalemia management in HF patients is warranted to prevent future recurrences and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Rowan et al. (2026) conducted a cohort in Heart failure and hyperkalemia (n=15,512). History of hyperkalemia vs. No history of hyperkalemia was evaluated on Recurrent hyperkalemia (K+ > 5.0 mmol/L) (OR 2.3, 95% CI 2.1-2.5). A history of hyperkalemia more than doubled the risk of recurrent hyperkalemia (OR 2.3) in heart failure patients, with 49.5% of the overall cohort experiencing a recurrence within 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: